ERC Einstein Rockefeller CUNY Center for AIDS Research

项目总结 ERC-CFAR：生物标志物和先进技术核心(BATC) 为了支持ERC-CFAR结束艾滋病毒流行的总体目标，Biomarker和Advanced 技术核心(BATC)提供最先进的技术、服务和咨询，以增强我们的 了解艾滋病毒的生物学和机制，并加快开发新的治疗方法 防病治病。BATC支持实施研究，以提高预先曝光的有效性 预防(PrEP)、暴露后预防(PEP)和治疗即预防(TasP)。BATC 基础设施支持现有的和早期的艾滋病毒/艾滋病研究人员以及新的调查人员 扩大他们的研究范围，包括爱因斯坦、洛克菲勒和纽约市立大学的艾滋病毒/艾滋病相关研究。领导层 提供独特的咨询服务，利用他们的经验发现内部和外部的机会 BATC。BATC为我们的调查人员和艾滋病毒和精神病学成员提供尖端服务 卫生科学工作组将完成对下一代艾滋病毒的研究、指导和培训 调查人员，招募艾滋病毒研究方面的资深调查人员，并在爱因斯坦范围内建立新的合作伙伴， 洛克菲勒和纽约州立大学等地区性学术中心。BATC的目标是：1)提供 拥有技术支持的调查人员，以检查和评估预防、治疗和治疗 治愈艾滋病毒感染并确定艾滋病毒的发病机制。BATC提供广泛的服务 包括生物标记物分析和抗逆转录病毒药物依从性的测量，这些对PrEP、PEP至关重要 和TasP研究。BATC分析体液、培养上清液和细胞裂解物中的免疫分子 和使用高通量多路平台的抗病毒药物药代动力学/药效学，ELISA和 质谱学。BATC提供从人类白细胞和人类血液中分离出的细胞类型 感染艾滋病毒(PWH)。BATC是临床和转化科学核心的联络人，负责处理血液 从爱因斯坦或洛克菲勒的PWH白血球中分离和冷冻各种类型的细胞，以供将来使用 ERC-CFAR调查人员。BATC将定制HIV RNA/DNA定量和进口的分析方法 建立尖端技术；2)为调查人员提供最先进的 蛋白质科学，支持艾滋病毒生物学、机制和治疗的研究。BATC提供了关键的 用于开发用于根除艾滋病毒的新生物制剂的蛋白质试剂，用于研究细胞和 体液免疫和大量用于蛋白质结构和生化表征的材料 以及对艾滋病毒感染和生命周期至关重要的组件。它提供了独特的基于细胞的分析来表征 受体-配体的相互作用，包括那些与抗体依赖的细胞介导的细胞毒性有关的作用，是一个关键的 疫苗和免疫疗法方面；3)实施和评估新的 纳入《生物多样性公约》的技术。BATC实施了生物信息学服务，并正在 评估纳入BATC的新技术，包括代谢组学和蛋白质组学。

PROJECT SUMMARY ERC-CFAR: BIOMARKER AND ADVANCED TECHNOLOGY CORE (BATC) To support the overarching goal of the ERC-CFAR to end the HIV epidemic, the Biomarker and Advanced Technology Core (BATC) provides state-of-the-art technologies, services and consultations to enhance our understanding of HIV biology and mechanisms and accelerate the development of novel approaches for prevention and cure. The BATC supports implementation research to improve the effectiveness of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) and treatment as prevention (TasP). The BATC infrastructure supports established and early stage HIV/AIDS researchers as well as new investigators who are expanding their research to include HIV/AIDS-related studies at Einstein, Rockefeller, and CUNY. The leadership provides unique consultation services that leverage their experience to identify opportunities within and outside the BATC. The BATC provides cutting-edge services for our investigators and members of the HIV and Mental Health Scientific Working Group to accomplish their research, mentors and trains the next generation of HIV investigators, recruits established investigators into HIV research, and forges new collaborations across Einstein, Rockefeller and CUNY and other regional academic centers. The Aims of the BATC are: 1) Provide investigators with technological support to examine and evaluate novel approaches to prevent, treat and cure HIV infection and to characterize HIV pathogenesis. The BATC provides a wide array of services including biomarker assays and measurement of antiretroviral drug adherence, which are critical for PrEP, PEP and TasP studies. The BATC analyzes body fluids, culture supernatants and cell lysates for immune molecules and antiviral drug pharmacokinetics/pharmacodynamics using high-throughput multiplex platforms, ELISAs, and mass spectrometry. The BATC provides isolated cell types from human leukopaks and from blood from people with HIV (PWH). The BATC serves as a liaison with the Clinical and Translational Science Core to process blood from PWH leukapharesed at Einstein or Rockefeller to isolate and freeze various cell types for future use by ERC-CFAR investigators. The BATC will customize assays for HIV RNA/DNA quantification and import and establish cutting edge technologies; 2) Provide investigators with state-of-the-art technologies in the Protein Sciences to support studies of HIV biology, mechanism, and treatment. The BATC provides critical protein reagents for development of novel biologics for HIV eradication, protein antigens to study cellular and humoral immunity, and large quantities of materials for structural and biochemical characterization of proteins and assemblies critical for HIV infection and life cycle. It provides unique cell-based assays to characterize receptor-ligand interactions, including those linked to antibody dependent cell mediated cytotoxicity, a critical aspect of vaccines and immunotherapies; 3) Implement and evaluate the utility and feasibility of new technologies for inclusion within BATC. The BATC implemented bioinformatics services and is evaluating new technologies for inclusion within the BATC, including metabolomics and proteomics.